Recent gains in clinical multiple sclerosis research

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 5, 2012, Pages 497-505

  Runia, T F ^a   van Pelt Gravesteijn, E D ^a   Hintzen, R Q ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Disease course; Epidemiology; Multiple sclerosis; Pediatric multiple sclerosis; Review

Indexed keywords

AQUAPORIN 4 ANTIBODY; AQUAPORUMAB; AZATHIOPRINE; CORTICOSTEROID; MONOCLONAL ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CHILDHOOD; CLINICAL RESEARCH; CORTICOSTEROID THERAPY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE EXACERBATION; EPSTEIN BARR VIRUS INFECTION; GENE LOCUS; GENETIC PREDISPOSITION; HUMAN; LIFE EXPECTANCY; MENTAL DETERIORATION; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; PARAMETERS; PATHOPHYSIOLOGY; PLASMAPHERESIS; PREVALENCE; REMISSION; RETINAL NERVE FIBER LAYER THICKNESS; RISK ASSESSMENT; RISK FACTOR; SUN EXPOSURE; VITAMIN BLOOD LEVEL;

EID: 84863885667     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712801661239     Document Type: Article

References (94)

1. Compston, A.; Coles, A. Multiple sclerosis. Lancet, 2002, 359(9313), 1221-1231.
2. Compston, A.; Coles, A. Multiple sclerosis. Lancet, 2008, 372(9648), 1502-1517.
3. Koch-Henriksen, N.; Sorensen, P.S. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol., 2010, 5, 520-532.
4. Kurtzke, J.F. Epidemiology of multiple sclerosis. Does this really point toward an etiology? Lectio Doctoralis. Neurol. Sci., 2000, 21(6), 383-403.
5. Acheson, E.D.; Bachrach, C.A.; Wright, F.M. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatr. Scand. Suppl., 1960, 35(147), 132-147.
6. Kurtzke, J.F.; Beebe, G.W.; Norman, J.E., Jr. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology, 1979, 29(9 Pt 1), 1228-1235.
7. McLeod, J.G.; Hammond, S.R.; Kurtzke, J.F. Migration and multiple sclerosis in immigrants to Australia from United Kingdom and Ireland: a reassessment. I. Risk of MS by age at immigration. J. Neurol., 2011, 258(6), 1140-1149.
8. Wallin, M.T.; Page, W.F.; Kurtzke, J.F. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann. Neurol., 2004, 55(1), 65-71.
9. Veldman, C.M.; Cantorna, M.T.; DeLuca, H.F. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys., 2000, 374(2), 334-338.
10. Chen, S.; Sims, G.P.; Chen, X.X.; Gu, Y.Y.; Lipsky, P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol., 2007, 179(3), 1634-1647.
11. Jeffery, L.E.; Burke, F.; Mura, M.; Zheng, Y.; Qureshi, O.S.; Hewison, M.; Walker, L.S.; Lammas, D.A.; Raza, K.; Sansom, D.M. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J. Immunol., 2009, 183(9), 5458-5467.
12. Adorini, L.; Penna, G. Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol., 2008, 4(8), 404-412.
13. Correale, J.; Ysrraelit, M.C.; Gaitan, M.I. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain, 2009, 132(Pt 5), 1146-1160.
14. Smolders, J.; Thewissen, M.; Peelen, E.; Menheere, P.; Tervaert, J.W.; Damoiseaux, J.; Hupperts, R. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One, 2009, 4(8), e6635.
15. Orton, S.M.; Ramagopalan, S.V.; Para, A.E.; Lincoln, M.R.; Handunnetthi, L.; Chao, M.J.; Morahan, J.; Morrison, K.M.; Sadovnick, A.D.; Ebers, G.C. Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians. J. Neurol. Sci., 2011, 305(1-2), 116-120.
16. Van der Mei, I.A.; Ponsonby, A.L.; Dwyer, T.; Blizzard, L.; Simmons, R.; Taylor, B.V.; Butzkueven, H.; Kilpatrick, T. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. Br. Med. J., 2003, 327(7410), 316.
17. Munger, K.L.; Levin, L.I.; Hollis, B.W.; Howard, N.S.; Ascherio, A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA, 2006, 296(23), 2832-2838.
18. Simpson, S., Jr.; Taylor, B.; Blizzard, L.; Ponsonby, A.L.; Pittas, F.; Tremlett, H.; Dwyer, T.; Gies, P.; van der Mei, I. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann. Neurol., 2010, 68(2), 193-203.
19. Lucas, R.M.; Ponsonby, A.L.; Dear, K.; Valery, P.C.; Pender, M.P.; Taylor, B.V.; Kilpatrick, T.J.; Dwyer, T.; Coulthard, A.; Chapman, C.; van der Mei, I.; Williams, D.; McMichael, A.J. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology, 2011, 76(6), 540-548.
20. Hart, P.H.; Gorman, S.; Finlay-Jones, J.J. Modulation of the immune system by UV radiation: more than just the effects of vitamin D? Nat. Rev. Immunol., 2011, 11(9), 584-596.
21. Simpson, S., Jr.; Blizzard, L.; Otahal, P.; Van der Mei, I.; Taylor, B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J. Neurol. Neurosurg. Psychiatry, 2011, 82(10), 1132-1141.
22. Handel, A.E.; Giovannoni, G.; Ebers, G.C.; Ramagopalan, S.V. Environmental factors and their timing in adult-onset multiple sclerosis. Nat. Rev. Neurol., 2010, 6(3), 156-166.
23. Hernan, M.A.; Zhang, S.M.; Lipworth, L.; Olek, M.J.; Ascherio, A. Multiple sclerosis and age at infection with common viruses. Epidemiology, 2001, 12(3), 301-306.
24. Orton, S.M.; Herrera, B.M.; Yee, I.M.; Valdar, W.; Ramagopalan, S.V.; Sadovnick, A.D.; Ebers, G.C.; Canadian Collaborative Study Group. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol., 2006, 5(11), 932-936.
25. McDonald, W.I.; Compston, A.; Edan, G.; Goodkin, D.; Hartung, H.P.; Lublin, F.D.; McFarland, H.F.; Paty, D.W.; Polman, C.H.; Reingold, S.C.; Sandberg-Wollheim, M.; Sibley, W.; Thompson, A.; van den Noort, S.; Weinshenker, B.Y.; Wolinsky, J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol., 2001, 50(1), 121-127.
26. Polman, C.H.; Wolinsky, J.S.; Reingold, S.C. Multiple sclerosis diagnostic criteria: three years later. Mult. Scler., 2005, 11(1), 5-12.
27. Polman, C.H.; Reingold, S.C.; Edan, G.; Filippi, M.; Hartung, H.P.; Kappos, L.; Lublin, F.D.; Metz, L.M.; McFarland, H.F.; O'Connor, P.W.; Sandberg-Wollheim, M.; Thompson, A.J.; Weinshenker, B.G.; Wolinsky, J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol., 2005, 58(6), 840-846.
28. Fox, C.M.; Bensa, S.; Bray, I.; Zajicek, J.P. The epidemiology of multiple sclerosis in Devon: a comparison of the new and old classification criteria. J. Neurol. Neurosurg. Psychiatry, 2004, 75(1), 56-60.
29. Koch-Henriksen, N. The Danish Multiple Sclerosis Registry: a 50-year follow-up. Mult. Scler., 1999, 5(4), 293-296.
30. Pugliatti M.; Sotgiu S.; Rosati G. The worldwide prevalence of multiple sclerosis. Clin. Neurol. Neurosurg., 2002, 104(3), 182-191.
31. Kira, J.; Kanai, T.; Nishimura, Y.; Yamasaki, K.; Matsushita, S.; Kawano, Y.; Hasuo, K.; Tobimatsu, S.; Kobayashi, T. Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann. Neurol., 1996, 40(4), 569-574.
32. International Multiple Sclerosis Genetics C.; Wellcome Trust Case Control C.; Sawcer, S.; Hellenthal, G.; Pirinen, M.; Spencer, C.C.; Patsopoulos, N.A.; Moutsianas, L.; Dilthey, A.; Su, Z.; Freeman, C.; Hunt, S.E.; Edkins, S.; Gray, E.; Booth, D.R.; Potter, S.C.; Goris, A.; Band, G.; Oturai, A.B.; Strange, A.; Saarela, J.; Bellenguez, C.; Fontaine, B.; Gillman, M.; Hemmer, B.; Gwilliam, R.; Zipp, F.; Jayakumar, A.; Martin, R.; Leslie, S.; Hawkins, S.; Giannoulatou, E.; D'alfonso, S.; Blackburn, H.; Martinelli Boneschi, F.; Liddle, J.; Harbo, H.F.; Perez, M.L.; Spurkland, A.; Waller, M.J.; Mycko, M.P.; Ricketts, M.; Comabella, M.; Hammond, N.; Kockum, I.; McCann, O.T.; Ban, M.; Whittaker, P.; Kemppinen, A.; Weston, P.; Hawkins, C.; Widaa, S.; Zajicek, J.; Dronov, S.; Robertson, N.; Bumpstead, S.J.; Barcellos, L.F.; Ravindrarajah, R.; Abraham, R.; Alfredsson, L.; Ardlie, K.; Aubin, C.; Baker, A.; Baker, K.; Baranzini, S.E.; Bergamaschi, L.; Bergamaschi, R.; Bernstein, A.; Berthele, A.; Boggild, M.; Bradfield, J.P.; Brassat, D.; Broadley, S.A.; Buck, D.; Butzkueven, H.; Capra, R.; Carroll, W.M.; Cavalla, P.; Celius, E.G.; Cepok, S.; Chiavacci, R.; Clerget-Darpoux, F.; Clysters, K.; Comi, G.; Cossbum, M.; Cournu-Rebeix, I.; Cox, M.B.; Cozen, W.; Cree, B.A.; Cross, A.H.; Cusi, D.; Daly, M.J.; Davis, E.; de Bakker, P.I.; Debouverie, M.; D'hooghe, M.B.; Dixon, K.; Dobosi, R.; Dubois, B.; Ellinghaus, D.; Elovaara, I.; Esposito, F.; Fontenille, C.; Foote, S.; Franka, A.; Galimberti, D.; Ghezzi, A.; Glessner, J.; Gomez, R.; Gout, O.; Graham, C.; Grant, S.F.; Guerini, F.R.; Hakonarson, H.; Hall, P.; Hamsten, A.; Hartung, H.P.; Heard, R.N.; Heath, S.; Hobart, J.; Hoshi, M.; Infante-Duarte, C.; Ingram, G.; Ingram, W.; Islam, T.; Jagodic, M.; Kabesch, M.; Kermode, A.G.; Kilpatrick, T.J.; Kim, C.; Klopp, N.; Koivisto, K.; Larsson, M.; Lathrop, M.; Lechner-Scott, J.S.; Leone, M.A.; Leppä, V.; Liljedahl, U.; Bomfim, I.L.; Lincoln, R.R.; Link, J.; Liu, J.; Lorentzen, A.R.; Lupoli, S.; Macciardi, F.; Mack, T.; Marriott, M.; Martinelli, V.; Mason, D.; McCauley, J.L.; Mentch, F.; Mero, I.L.; Mihalova, T.; Montalban, X.; Mottershead, J.; Myhr, K.M.; Naldi, P.; Ollier, W.; Page, A.; Palotie, A.; Pelletier, J.; Piccio, L.; Pickersgill, T.; Piehl, F.; Pobywajlo, S.; Quach, H.L.; Ramsay, P.P.; Reunanen, M.; Reynolds, R.; Rioux, J.D.; Rodegher, M.; Roesner, S.; Rubio, J.P.; Rückert, I.M.; Salvetti, M.; Salvi, E.; Santaniello, A.; Schaefer, C.A.; Schreiber, S.; Schulze, C.; Scott, R.J.; Sellebjerg, F.; Selmaj, K.W.; Sexton, D.; Shen, L.; Simms-Acuna, B.; Skidmore, S.; Sleiman, P.M.; Smestad, C.; Sørensen, P.S.; Søndergaard, H.B.; Stankovich, J.; Strange, R.C.; Sulonen, A.M.; Sundgvist, E.; Syvänen, A.C.; Taddeo, F.; Taylor, B.; Blackwell, J.M.; Tienari, P.; Bramon, E.; Tourbah, A.; Brown, M.A.; Tronczynska, E.; Casas, J.P.; Tubridy, N.; Corvin, A.; Vickery, J.; Jankowski, J.; VilloSlada, P.; Markus, H.S.; Wang, K.; Mathew, C.G.; Wason, J.; Palmer, C.N.; Wichmann, H.E.; Plomin, R.; Willoughby, E.; Rautanen, A.; Winkelmann, J.; Wittig, M.; Trembath, R.C.; Yaouang, J.; Viswanathan, A.C.; Zhang, H.; Wood, N.W.; Zuvich, R.; Deloukas, P.; Langford, C.; Duncanson, A.; Oksenberg, J.R.; Pericak-Vance, M.A.; Haines, J.L.; Olsson, T.; Hillert, J.; Ivinson, A.J.; De Jager, P.L.; Peltonen, L.; Stewart, G.J.; Hafler, D.A.; Hauser, S.L.; McVean, G.; Donnelly, P.; Compston, A. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476(7359), 214-219.
33. Fisniku, L.K.; Brex, P.A.; Altmann, D.R.; Miszkiel, K.A.; Benton, C.E.; Lanyon, R.; Thompson, A.J.; Miller, D.H. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain, 2008, 131(Pt 3), 808-817.
34. Tintore, M.; Rovira, A.; Rio, J.; Nos, C.; Grive, E.; Tellez, N.; Pelayo, R.; Comabella, M.; Montalban, X. Is optic neuritis more benign than other first attacks in multiple sclerosis? Ann. Neurol., 2005, 57(2), 210-215.
35. Nilsson, P.; Larsson, E.M.; Maly-Sundgren, P.; Perfekt, R.; Sandberg-Wollheim, M. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J. Neurol., 2005, 252(4), 396-402.
36. Confavreux, C.; Vukusic, S. Age at disability milestones in multiple sclerosis. Brain, 2006, 129(Pt 3), 595-605.
37. Kremenchutzky, M.; Rice, G.P.; Baskerville, J.; Wingerchuk, D.M.; Ebers, G.C. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain, 2006, 129(Pt 3), 584-594.
38. Confavreux, C.; Vukusic, S.; Adeleine, P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain, 2003, 126(Pt 4), 770-782.
39. Scalfari, A.; Neuhaus, A.; Daumer, M.; Ebers, G.C.; Muraro, P.A. Age and disability accumulation in multiple sclerosis. Neurology, 2011, 77(13), 1246-1252.
40. Degenhardt, A.; Ramagopalan, S.V.; Scalfari, A.; Ebers, G.C. Clinical prognostic factors in multiple sclerosis: a natural history review. Nat. Rev. Neurol., 2009, 5(12), 672-682.
41. Grytten, T.N.; Lie, S.A.; Aarseth, J.H.; Nyland, H.; Myhr, K.M. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult. Scler., 2008, 14(9), 1191-1198.
42. Weinshenker, B.G. The natural history of multiple sclerosis. Neurol. Clin., 1995, 13(1), 119-146.
43. Sadovnick, A.D.; Eisen, K.; Ebers, G.C.; Paty, D.W. Cause of death in patients attending multiple sclerosis clinics. Neurology, 1991, 41(8), 1193-1196.
44. Feinstein, A. Mood disorders in multiple sclerosis and the effects on cognition. J. Neurol. Sci., 2006, 245(1-2), 63-66.
45. Feinstein, A.; Roy, P.; Lobaugh, N.; Feinstein, K.; O'Connor, P.; Black, S. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology, 2004, 62(4), 586-590.
46. Feinstein, A. Multiple sclerosis and depression. Mult. Scler., 2011, 17(11), 1276-1281.
47. Confavreux, C.; Hutchinson, M.; Hours, M.M.; Cortinovis-Tourniaire, P.; Moreau, T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med., 1998, 339(5), 285-291.
48. Vukusic, S.; Hutchinson, M.; Hours, M.; Moreau, T.; Cortinovis-Tourniaire, P.; Adeleine, P.; Confraveux, C.; The Pregnancy In Multiple Sclerosis Group. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain, 2004, 127(Pt 6), 1353-1360.
49. Langer-Gould, A.; Huang, S.M.; Gupta, R.; Leimpeter, A.D.; Greenwood, E.; Albers, K.B.; van den Eeden, S.K.; Nelson, L.M. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch. Neurol., 2009, 66(8), 958-963.
50. Airas, L.; Jalkanen, A.; Alanen, A.; Pirttila, T.; Marttila, R.J. Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis. Neurology, 2010, 75(5), 474-476.
51. Iorio, R.; Nociti, V.; Frisullo, G.; Patanella, A.K.; Tonali, P.A.; Batocchi, A.P. Breastfeeding and multiple sclerosis. Arch. Neurol., 2009, 66(12), 1580.
52. Poser, C.M.; Paty, D.W.; Scheinberg, L.; McDonald, W.I.; Davis, F.A.; Ebers, G.C.; Johnson, K.P.; Sibley, W.A.; Silberberg, D.H.; Tourtellotte, W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol., 1983, 13(3), 227-231.
53. Polman, C.H.; Reingold, S.C.; Banwell, B.; Clanet, M.; Cohen, J.A.; Filippi, M.; Fujihara, K.; Havrdova, E.; Hutchinson, M.; Kappos, L.; Lublin, F.D.; Montalban, X.; O'Connor, P.; Sandberg-Wollheim, M.; Thompson, A.J.; Waubant, E.; Weinshenker, B.; Wolinsky, J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol., 2011, 69(2), 292-302.
54. Gomez-Moreno, M.; Diaz-Sanchez, M.; Ramos-Gonzalez, A. Application of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Spanish cohort of patients with clinically isolated syndromes. Mult. Scler., 2012, 18(1), 39-44.
55. Confavreux, C.; Vukusic, S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin. Neurol. Neurosurg., 2006, 108(3), 327-332.
56. Zivadinov, R. Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology, 2007, 68(22 Suppl 3), S72-S82.; discussion S91-S96.
57. Barkhof, F.; Calabresi, P.A.; Miller, D.H.; Reingold, S.C. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat. Rev. Neurol., 2009, 5(5), 256-266.
58. Costello, F.; Coupland, S.; Hodge, W.; Lorello, G.R.; Koroluk, J.; Pan, Y.I.; Freedman, M.S.; Zackon, D.H.; Kardon, R.H. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann. Neurol., 2006, 59(6), 963-969.
59. Fisher, J.B.; Jacobs, D.A.; Markowitz, C.E.; Galetta, S.L.; Volpe, N.J.; Nano-Schiavi, M.L.; Baier, M.L.; Frohman, E.M.; Winslow, H.; Frohman, T.C.; Calabresi, P.A.; Maguire, M.G.; Cutter, G.R.; Balcer, L.J. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology, 2006, 113(2), 324-332.
60. Gordon-Lipkin, E.; Chodkowski, B.; Reich, D.S.; Smith, S.A.; Pulicken, M.; Balcer, L.J.; Frohman, E.M.; Cutter, G.; Calabressi, P.A. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology, 2007, 69(16), 1603-1609.
61. Cettomai, D.; Pulicken, M.; Gordon-Lipkin, E.; Salter, A.; Frohman, T.C.; Conger, A.; Zhang, X.; Cutter, D.; Balcer, L.J.; Frohman, E.M.; Calabressi, P.A. Reproducibility of optical coherence tomography in multiple sclerosis. Arch. Neurol., 2008, 65(9), 1218-1222.
62. Banwell, B.; Ghezzi, A.; Bar-Or, A.; Mikaeloff, Y.; Tardieu, M. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol., 2007, 6(10), 887-902.
63. Banwell, B.; Kennedy, J.; Sadovnick, D.; Arnold, D.L.; Magalhaes, S.; Wambera, K.; Connolly, M.B.; Yager, J.; Mah, J.K.; Shah, N.; Sebire, G.; Meaney, B.; Dilenge, M.E.; Lortie, A.; Whiting, S.; Doja, A.; Levin, S.; MacDonald, E.A.; Meek, D.; Wood, E.; Lowry, N.; Buckley, D.; Yim, C.; Awuku, M.; Guimond, C.; Cooper, P.; Grand'Maison, F.; Baird, J.B.; Bhan, V.; Bar-Or, A. Incidence of acquired demyelination of the CNS in Canadian children. Neurology, 2009, 72(3), 232-239.
64. Langer-Gould, A.; Zhang, J.L.; Chung, J.; Yeung, Y.; Waubant, E.; Yao, J. Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology, 2011, 77(12), 1143-1148.
65. Venkateswaran, S.; Banwell, B. Pediatric multiple sclerosis. Neurologist, 2010, 16(2), 92-105.
66. Renoux, C.; Vukusic, S.; Mikaeloff, Y.; Edan, G.; Clanet, M.; Dubois, B.; Debouverie, M.; Brochet, B.; Lebrun-Frenay, C.; Pelletier, J.; Moreau, T.; Lubetzki, C.; Vermersch, P.; Roullet, E.; Magy, L.; Tardieu, M.; Suissa, S.; Confavreux, C.; Adult Neurology Departments KIDMUS Study Group. Natural history of multiple sclerosis with childhood onset. N. Engl. J. Med., 2007, 356(25), 2603-2613.
67. Krupp, L.B.; Banwell, B.; Tenembaum, S.; International Pediatric MSSG. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology, 2007, 68(16 Suppl 2), S7-S12.
68. Hahn, J.S.; Pohl, D.; Rensel, M.; Rao, S.; International Pediatric MSSG. Differential diagnosis and evaluation in pediatric multiple sclerosis. Neurology, 2007, 68(16 Suppl 2), S13-S22.
69. Mikaeloff, Y.; Suissa, S.; Vallee, L.; Lubetzki, C.; Ponsot, G.; Confavreux, C.; Tardieu, M.; KIDMUS Study Group. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J. Pediatr., 2004, 144(2), 246-252.
70. Banwell, B.; Bar-Or, A.; Arnold, D.L.; Sadovnick, D.; Narayanan, S.; McGowan, M.; O'Mahny, J.; Magalhaes, S.; Hanwell, H.; Vieth, R.; Tellier, R.; Vincent, T.; Disanto, G.; Ebers, G.; Wambera, K.; Connolly, M.B.; Yager, J.; Mah, J.K.; Booth, F.; Sebire, G.; Callen, D.; Meaney, B.; Dilenge, M.E.; Lortie, A.; Pohl, D.; Doja, A.; Venketaswaran, S.; Levin, S.; Macdonald, E.A.; Meek, D.; Wood, E.; Lowry, N.; Buckley, D.; Yim, C.; Awuku, M.; Cooper, P.; Grand'Maison, F.; Baird, J.B.; Bhan, V.; Marrie, R.A. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol., 2011, 10(5), 436-445.
71. Gorman, M.P.; Healy, B.C.; Polgar-Turcsanyi, M.; Chitnis, T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch. Neurol., 2009, 66(1), 54-59.
72. Pohl, D.; Rostasy, K.; Reiber, H.; Hanefeld, F. CSF characteristics in early-onset multiple sclerosis. Neurology, 2004, 63(10), 1966-1967.
73. Waubant, E.; Chabas, D.; Okuda, D.T.; Glenn, O.; Mowry, E.; Henry, R.G.; Strober, J.B.; Soares, B.; Wintermark, M.; Pelletier, D. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch. Neurol., 2009, 66(8), 967-971.
74. Sedani, S.; Lim, M.; Hemingway, C.; Wassmer, E.; Absoud, M. Paediatric multiple sclerosis: examining utility of the McDonald 2010 criteria. Mult. Scler., 2012, 18(5), 679-682.
75. Verhey, L.H.; Branson, H.M.; Shroff, M.M.; Callen, D.J.; Sled, J.G.; Narayanan, S.; Sadovnick, A.D.; Bar-Or, A.; Arnold, D.L.; Marrie, R.A.; Banwell, B.; Canadian Pediatric Demyelinating Disease Network. MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol., 2011, 10(12), 1065-1073.
76. Tenembaum, S.N. Therapy of multiple sclerosis in children and adolescents. Clin. Neurol. Neurosurg., 2010, 112(7), 633-640.
77. Pohl, D.; Waubant, E.; Banwell, B.; Chabas, D.; Chitnis, T.; Weinstock-Guttman, B.; Tenembaum, S.; International Pediatric MS Study Group. Treatment of pediatric multiple sclerosis and variants. Neurology, 2007, 68(16 Suppl 2), S54-S65.
78. Ghezzi, A. Therapeutic strategies in childhood multiple sclerosis. Ther. Adv. Neurol. Disord., 2010, 3(4), 217-228.
79. Ghezzi, A.; Pozzilli, C.; Grimaldi, L.M.; Brescia Morra, V.; Bortolon, F.; Capra, R.; Filippi, M.; Moiola, L.; Rocca, M.A.; Rottoli, M.; Sarchielli, P.; Zaffaroni, M.; Comi, G. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology, 2010, 75(10), 912-917.
80. Simone, I.L.; Carrara, D.; Tortorella, C.; Liguori, M.; Lepore, V.; Pellegrini, F.; Bellacosa, A.; Ceccarelli, A.; Pavone, I.; Livrea, P. Course and prognosis in early-onset MS: comparison with adultonset forms. Neurology, 2002, 59(12), 1922-1928.
81. Wingerchuk, D.M.; Lennon, V.A.; Pittock, S.J.; Lucchinetti, C.F.; Weinshenker, B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology, 2006, 66(10), 1485-1489.
82. Lennon, V.A.; Wingerchuk, D.M.; Kryzer, T.J.; Pittock, S.J.; Lucchinetti, C.F.; Fujihara, K.; Nakashima, I.; Weinshenker, B.G. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet, 2004, 364(9451), 2106-2112.
83. Lennon, V.A.; Kryzer, T.J.; Pittock, S.J.; Verkman, A.S.; Hinson, S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med., 2005, 202(4), 473-477.
84. Miller, D.H.; Weinshenker, B.G.; Filippi, M.; Banwell, B.L.; Cohen, J.A.; Freedman, M.S.; Galetta, S.L.; Hutchinson, M.; Johnson, R.T.; Kappos, L.; Kira, J.; Lublin, F.D.; McFarland, H.F.; Montalban, X.; Panitch, H.; Richert, J.R.; Reingold, S.C.; Polman, C.H. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult. Scler., 2008, 14(9), 1157-1174.
85. Wingerchuk, D.M.; Hogancamp, W.F.; O'Brien, P.C.; Weinshenker, B.G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology, 1999, 53(5), 1107-1114.
86. Wingerchuk, D.M.; Lennon, V.A.; Lucchinetti, C.F.; Pittock, S.J.; Weinshenker, B.G. The spectrum of neuromyelitis optica. Lancet Neurol., 2007, 6(9), 805-815.
87. Waters, P.; Vincent, A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int. MS J., 2008, 15(3), 99-105.
88. De Vidi, I.; Boursier, G.; Delouche, N.; Portales, P.; Cadars, E.; Bouthier, M.; Mettling, C.; Lin, Y.L.; Thouvenot, E.; Carlander, B.; Camu, W.; Antel, J.P.; Bar-Or, A.; Zephir, H.; Vermersch, P.; De Seze, J.; Corbeau, P.; Eliaou, J.F.; Vincent, T. Strategy for antiaquaporin-4 auto-antibody identification and quantification using a new cell-based assay. Clin. Immunol., 2011, 138(3), 239-246.
89. Ketelslegers, I.A.; Modderman, P.W.; Vennegoor, A.; Killestein, J.; Hamann, D.; Hintzen, R.Q. Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients. Mult. Scler., 2011, 17(12), 1527-1530.
90. McKeon, A.; Fryer, J.P.; Apiwattanakul, M.; Lennon, V.A.; Hinson, S.R.; Kryzer, T.J.; Lucchinetti, C.F.; Weinschenker, B.G.; Wingerchuk, D.M.; Shuster, E.A.; Pittock, S.J. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch. Neurol., 2009, 66(9), 1134-1138.
91. Sellner, J.; Boggild, M.; Clanet, M.; Hintzen, R.Q.; Illes, Z.; Montalban, X.; Du Pasquier, R.A.; Polman, C.H.; Sorensen, P.S.; Hemmer, B. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur. J. Neurol., 2010, 17(8), 1019-1032.
92. Collongues, N.; Marignier, R.; Zephir, H.; Papeix, C.; Blanc, F.; Ritleng, C.; Tchikviladzé, M.; Outteryck, O.; Vukusic, S.; Fleury, M.; Fontaine, B.; Brassat, D.; Clanet, M.; Milh, M.; Pelletier, J.; Audoin, B.; Ruet, A.; Lebrun-Frenay, C.; Thouvenot, E.; Camu, W.; Debouverie, M.; Créange, A.; Moreau, T.; Labauge, P.; Castelnovo, G.; Edan, G.; Le, Page, E.; Defer, G.; Barroso, B.; Heinzlef, O.; Gout, O.; Rodriguez, D.; Wiertlewski, S.; Laplaud, D.; Borgel, F.; Tourniaire, P.; Grimaud, J.; Brochet, B.; Vermersch, P.; Confavreux, C.; de Seze, J. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology, 2010, 74(9), 736-742.
93. Verkman, A.S.; Ratelade, J.; Rossi, A.; Zhang, H.; Tradtrantip, L. Aquaporin-4: orthogonal array assembly, CNS functions, and role in neuromyelitis optica. Acta Pharmacol. Sin., 2011, 32(6), 702-710.
94. Tradtrantip, L.; Zhang, H.; Saadoun, S.; Phuan, P.W.; Lam, C.; Papadopoulos, M.C.; Bennett, J.L.; Verkman, A.S. Aquaporumab: a non-pathogenic anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. 2011.;5th Joint triennial congress of the European and Americas Committees for treatment and research in multiple sclerosis. Amsterdam, The Netherlands. 2011.